Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Med Mycol ; 55(7): 748-753, 2017 Oct 01.
Artigo em Inglês | MEDLINE | ID: mdl-28053149

RESUMO

A promising approach for the eradication of biofilm formed by the yeast Candida albicans seems to be photodynamic inactivation (PDI). This work presents a use of methylene blue (MB, 1 mM) irradiated with a red laser (output power 190 mW/cm2, wavelength 660 nm) for the eradication of a biofilm formed by the fluconazole-resistant (FLC-resistant) strain C. albicans CY 1123 compared to the standard strain C. albicans SC5314. The periods of irradiation corresponded to the fluence of 15, 23 and 57 J/cm2. Effectiveness of PDI was evident with following percentage of survived biofilm cells: 24.57, 23.46, and 22.29% for SC5314 and 40.28, 17.91, and 5.89% for CY 1123, respectively, compared to the samples without irradiation. Light and confocal laser scanning microscopy confirmed the effectiveness of PDI. However, the morphological form of C. albicans seems to play an important role as well, since prolonged duration of irradiation did not increase efficiency of PDI on C. albicans SC5314. An experiment with the yeast-to-hyphae transition revealed that the FLC-resistant strain expressed a markedly reduced capacity to form hyphae compared to SC5314. We summarized that PDI was effective on biofilm formed by the FLC-resistant strain, but resistance most likely did not play significant role in PDI. Additionally, we observed differences in susceptibility to PDI between biofilms composed of the mycelia and only of the yeasts, and finally, the employment of a laser in PDI enabled a decreasing period of irradiation while maintaining the high effectiveness of PDI.


Assuntos
Antifúngicos/farmacologia , Biofilmes/efeitos dos fármacos , Candida albicans/efeitos dos fármacos , Lasers , Azul de Metileno/farmacologia , Fármacos Fotossensibilizantes/farmacologia , Biofilmes/efeitos da radiação , Candida albicans/fisiologia , Candida albicans/efeitos da radiação , Farmacorresistência Fúngica , Fluconazol/farmacologia , Humanos , Hifas/efeitos dos fármacos , Hifas/efeitos da radiação , Viabilidade Microbiana/efeitos dos fármacos
2.
Antonie Van Leeuwenhoek ; 110(9): 1219-1226, 2017 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-28593476

RESUMO

With emerging fungal infections and developing resistance, there is a need for understanding the mechanisms of resistance as well as its clinical impact while planning the treatment strategies. Several approaches could be taken to overcome the problems arising from the management of fungal diseases. Besides the discovery of novel effective agents, one realistic alternative is to enhance the activity of existing agents. This strategy could be achieved by combining existing antifungal agents with other bioactive substances with known activity profiles (combination therapy). Azole antifungals are the most frequently used class of substances used to treat fungal infections. Fluconazole is often the first choice for antifungal treatment. The aim of this work was to study potential synergy between azoles and 1,4-dihydropyridine-2,3,5-tricarboxylate (termed derivative H) in order to control fungal infections. This article points out the synergy between azoles and newly synthesized derivative H in order to fight fungal infections. Experiments confirmed the role of derivative H as substrate/inhibitor of fungal transporter Cdr1p relating to increased sensitivity to fluconazole. These findings, plus decreased expression of ERG11, are responsible for the synergistic effect.


Assuntos
Antifúngicos/farmacologia , Candida albicans/efeitos dos fármacos , Di-Hidropiridinas/farmacologia , Fluconazol/farmacologia , Regulação Fúngica da Expressão Gênica/efeitos dos fármacos , Transportadores de Cassetes de Ligação de ATP/antagonistas & inibidores , Transportadores de Cassetes de Ligação de ATP/genética , Antifúngicos/síntese química , Antifúngicos/uso terapêutico , Candida albicans/genética , Candidíase/tratamento farmacológico , Di-Hidropiridinas/síntese química , Di-Hidropiridinas/uso terapêutico , Farmacorresistência Fúngica/efeitos dos fármacos , Sinergismo Farmacológico , Fluconazol/uso terapêutico , Proteínas Fúngicas/antagonistas & inibidores , Proteínas Fúngicas/genética , Humanos , Testes de Sensibilidade Microbiana , Mutação , Esterol 14-Desmetilase/genética
3.
Microb Drug Resist ; 25(6): 805-812, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-30785845

RESUMO

Aim: This work studied the impact of the quorum-sensing molecule, farnesol (FAR), on fluconazole (FLC)-resistant Candida albicans isolate CY 1123 compared with the susceptible standard strain C. albicans SC5314. The genes encoding efflux pumps belonging to the ATP-binding cassette (ABC) and major facilitator superfamilies, together with overexpression or point mutation of the ERG11 gene, are the main resistance mechanisms to azole antifungal drugs. Results: The upregulation of genes coding for CDR1, CDR2, and MDR1 were confirmed by qPCR with respect to the housekeeping gene ACT1 in the resistant strain. The contribution of the ERG11 gene was also observed. Markedly, increased pump activity (Cdr1 and/or Cdr2) in the CY 1123 strain was confirmed using diS-C3(3) assay. However, the addition of FAR to the yeasts diminished the difference in staining levels between the SC5314 and CY 1123 strains, demonstrating the concentration-dependent character that could be caused by an effective modulation of Cdr pumps. FAR (60 and 100 µM) was also able to decrease the minimal inhibitory concentrations (MIC50), denoting the inhibition of planktonic cells by 50%, from 8 to 4 µg/mL of FLC when the resistant strain CY 1123 was not cultivated with FLC. However, when it was exposed to 64 µg/mL of FLC, the MIC50 shifted from 64 to 8 µg/mL. Conclusion: Besides the many other effects of FAR on eukaryotic and prokaryotic cells, it also affects ABC efflux transporters, resulting in changes in resistance to azoles in C. albicans isolates. However, this effect is dependent on FAR concentrations.


Assuntos
Antifúngicos/farmacologia , Candida albicans/efeitos dos fármacos , Farmacorresistência Fúngica/efeitos dos fármacos , Farneseno Álcool/farmacologia , Fluconazol/farmacologia , Transportadores de Cassetes de Ligação de ATP/metabolismo , Transporte Biológico/efeitos dos fármacos , Candida albicans/metabolismo , Proteínas Fúngicas/metabolismo , Proteínas de Membrana Transportadoras/metabolismo , Testes de Sensibilidade Microbiana/métodos
4.
Folia Microbiol (Praha) ; 63(3): 363-371, 2018 May.
Artigo em Inglês | MEDLINE | ID: mdl-29234974

RESUMO

Farnesol (FAR) has already demonstrated an inhibitory effect on Candida albicans biofilm. The aim of this work was to determine the effectiveness of externally added FAR in combination with fluconazole (FLC) on Candida albicans biofilm and on regulation of the ergosterol genes ERG20, ERG9, and ERG11. The effectiveness of compounds was determined by MTT assay and evaluated by the minimal inhibitory concentrations reducing a sessile biofilm to 50% activity (0.5 µg/mL and 200 µmol/L for FLC and FAR, respectively). These concentrations as well as 30 and 100 µmol/L FAR were selected for a study of the effectiveness of the FAR/FLC combination. The reduction in biofilm robustness mainly caused by the presence of 200 µmol/L FAR-alone or in combination with FLC-was accompanied by a significant inhibition of the yeast-to-hyphae transition that was observed by light microscopy and CLSM. Results from qRT-PCR indicated that while 30 µmol/L FAR only slightly regulated the expression of all 3 genes in the 48-h biofilm, the presence of 200 µmol/L FAR downregulated all the tested genes. However, the addition of 0.5 µg/mL of FLC to the samples with 200 µmol/L FAR restored the downregulation of the ERG20 and ERG11 genes to the control level. Moreover, the gene ERG9 was slightly upregulated. In summary, FAR acted via multiple effects on the C. albicans biofilm, but only a higher concentration of FAR proved to be effective.


Assuntos
Antifúngicos/farmacologia , Biofilmes/efeitos dos fármacos , Candida albicans/crescimento & desenvolvimento , Farneseno Álcool/farmacologia , Fluconazol/farmacologia , Regulação Fúngica da Expressão Gênica/efeitos dos fármacos , Biofilmes/crescimento & desenvolvimento , Candida albicans/efeitos dos fármacos , Relação Dose-Resposta a Droga , Sinergismo Farmacológico , Ergosterol/genética , Ergosterol/metabolismo , Genes Fúngicos/genética , Hifas/efeitos dos fármacos , Redes e Vias Metabólicas/efeitos dos fármacos , Testes de Sensibilidade Microbiana
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA